Novartis first half net profits up 29 percent / Photo: GABRIEL MONNET - AFP
-
Arteta coy over Lewis-Skelly's Arsenal future after 'emotional' celebration
-
Infantino future should be decided by election says African football chief
-
Romania shuts down nuclear plant as Danube drops
-
Man City star Doku signs five-year contract extension
-
German steel giant Thyssenkrupp weighs options as Rhine drops
-
Fabien Barthez joins Zidane's new France coaching setup
-
US ambassador denounces settler siege as Israel dispatches troops
-
Taiwan chokes mobile internet speeds in drill for Chinese attack
-
Hasan takes 6-55 as Bangladesh claim opening day of Australia Test
-
From Chinese AI to Global ETFs: STARTRADER Launches 45 New 24/7 Stock and ETF CFDs
-
Taiwan says AI agents used in cyberattacks targeting island
-
Tech stocks enjoy rebound after US inflation on mixed day for markets
-
Japan protests Putin's first visit to disputed islands
-
Hasan takes 6-55 as Bangladesh bundle out Australia for 198
-
Kiss wants fit-again Wallabies playmaker Gordon to 'open up' Japan
-
Swiatek sinks Svitolina to set up Rybakina title clash in Toronto
-
British eccentrics push humble garden shed to new heights
-
Australia's Pallister shines, mixed relay record falls as Pan Pacs open
-
Zambia votes with president's economic record on the line
-
Hasan puts Bangladesh in charge as Australia struggle to 183-8
-
Germany's dry rivers spark battle on engineering vs restoration
-
Putin visits Kuril islands claimed by Japan
-
Senators demand inquiry into conditions aboard USS Abraham Lincoln
-
Swiatek downs Svitolina to reach first WTA final of 2026
-
All Blacks' Proctor out of South Africa series, Mo'unga called up
-
Jones says Japan 'watching videos of geese' for Australia clash
-
Bangladesh quick Hasan reduces Australia to 74-4 at lunch
-
Bloodied but unbowed, defending champ Shelton reaches Montreal final
-
Seoul tech leads Asian stock gains as traders cheer US inflation
-
Wallabies make eight changes for return Japan Test
-
Farage and Count Binface go head-to-head in snap UK poll
-
Messi returns after father's death but Miami knocked out of Leagues Cup
-
Afghan students divided over smartphone ban at universities
-
Outflanked by AI, stars fade for South Korea's blind fortune-tellers
-
Japan go back to school for second Australia Test
-
Venezuela govt, opposition wrap up round of post-Maduro talks
-
Matthew McConaughey on his sweet return to the big screen
-
Five things to know about Zambia as it goes to the polls
-
President's economic record on the line as Zambia votes
-
Nakashima holds off Jodar to book first ATP Masters final in Montreal
-
U.S. Polo Assn. Takes No. 1 Spot for All Sports Brands and Climbs to No. 22 Overall on License Global's 2026 'Top Global Licensors' Ranking
-
Grieving Messi available for Miami in Leagues Cup clash
-
Trump 'low-key' bets on economic pressure against Iran
-
Colombia enters 'final phase' of quake search as toll hits 265
-
Pitch invaders take selfies with Fernandes during Man Utd friendly
-
Father-figure Christie helps guide Kounta to European silver
-
No-stress Sabalenka won't fret over lackluster 2026 results
-
McIlroy returns to St. Jude to launch marathon PGA playoff push
-
Hometown hero Hudson-Smith basks in Euro glory
-
Guimaraes makes Arsenal debut in Como friendly
Novartis first half net profits up 29 percent
Swiss pharmaceuticals giant Novartis posted Thursday a 29 percent increase in first-half net income, at $7.6 billion -- and unveiled its new chief financial officer.
The Basel-based firm's net sales increased 12 percent to nearly $27.3 billion between January and June, it said in a statement.
Generic competition reduced its sales by two percent.
In the first half of 2025, sales of Entresto -- its flagship drug to treat chronic heart failure -- reached $4.6 billion, up 22 percent. Generic versions are expected to hit the market in the second half of the year.
Novartis chief executive Vas Narasimhan also pointed to the strong performance of other treatments such as Kisqali, for breast cancer, and Pluvicto, for prostate cancer.
The group also announced a change in its financial leadership due to take place next year.
Mukul Mehta, the head of business planning and analysis in digital finance and tax, will become the new chief financial officer in March.
He will succeed Harry Kirsch, who has held the position since 2013. Kirsch is retiring after 22 years with the company.
P.Serra--PC
